CIBMTR Reporting Implementation Guide
0.1.6 - Trial Use 1

This page is part of the CIBMTR Reporting Implementation Guide (v0.1.6: Release Draft) based on FHIR R4. This is the current published version. For a full list of available versions, see the Directory of published versions

Table of Contents

...0 Table of Contents
...1 Home
...2 Access Credentials
...3 Appendices
...4 Bundles
...5 Connection Guide R 4
...6 CRID Assignment
...7 Cytogenetics
...8 Direct FHIR STU 3
...9 Endpoints
...10 Example Code
...11 Form 2450
...12 Laboratory Observations
...13 Medications
...14 Patient
....15 Artifacts Summary
....15.1 CIBMTR Cytogenetics Profile
....15.2 CIBMTR Observation Laboratory Results: Priority Variables
....15.3 CIBMTR Observation Laboratory Results Profile (us-core)
....15.4 CIBMTR Patient Profile (us-core)
....15.5 CIBMTR Additional Drugs in Peri-Transplant Period
....15.6 CIBMTR GVHD Prophylaxis Medication
....15.7 CIBMTR Medication (us-core)
....15.8 CIBMTR Medication Administration (mcode)
....15.9 CIBMTR Medication Request (mcode)
....15.10 CIBMTR Mobilizing Agents Medication
....15.11 CIBMTR Planned Post-HCT Disease Therapy Medication
....15.12 CIBMTR Prep Regimen Medication
....15.13 CIBMTR Prior Exposure Medication
....15.14 Auto Differential panel - Blood (57023-4)
....15.15 CBC panel - Blood by Automated count (58410-2)
....15.16 CBC W Auto Differential panel - Blood (57021-8)
....15.17 CBC W Differential panel, method unspecified - Blood (69742-5)
....15.18 CBC W Ordered Manual Differential panel - Blood (57782-5)
....15.19 Differential panel, method unspecified - Blood (69738-3)
....15.20 Erythrocyte morphology panel - Blood (58408-6)
....15.21 GVHD ICD-10 Codes
....15.22 GVHD SNOMED CT Codes
....15.23 GVHD Type Value Set
....15.24 Disorders of hematopoietic structure
....15.25 Leukocyte morphology panel - Blood (58407-8)
....15.26 Manual Differential panel - Blood (24318-8)
....15.27 Platelet morphology panel - Blood (58406-0)
....15.28 Presence Answer List
....15.29 CIBMTR Priority Variables Value Set (FY21)
....15.30 CIBMTR Priority Variables Value Set (FY22)
....15.31 CIBMTR Priority Variables Value Set for Epic App (FY21)
....15.32 RxNorm - Additional Drugs in Peri-Transplant Period
....15.33 RxNorm - Alemtuzumab
....15.34 RxNorm - All of Form 2400
....15.35 RxNorm - Anti-Thymocyte Globulin
....15.36 RxNorm - Bortezomib
....15.37 RxNorm - Busulfan
....15.38 RxNorm - Carmustine
....15.39 RxNorm - Cyclophosphamide
....15.40 RxNorm - Cytarabine
....15.41 RxNorm - Defibrotide
....15.42 RxNorm - Etoposide
....15.43 RxNorm - Fludarabine
....15.44 RxNorm - GVHD Prophylaxis
....15.45 RxNorm - Melphalan
....15.46 RxNorm - Mobilizing Agents (auto only)
....15.47 RxNorm - Post-HCT Disease Therapy Planned
....15.48 RxNorm - Prep Regimen
....15.49 RxNorm - Prior Exposure: Potential Study Eligibility
....15.50 RxNorm - Rituximab
....15.51 RxNorm - Thiotepa
....15.52 RxNorm - Treosulfan
....15.53 RxNorm - Ursodiol
....15.54 SNOMED Myelodysplastic Diseases
....15.55 Smear morphology panel - Blood (34994-4)
....15.56 ABOBloodGroupObservationLOINC
....15.57 ABOBloodGroupObservationSNOMED
....15.58 ABORhObservationLOINC
....15.59 ABORhObservationSNOMED
....15.60 AlbuminObservation
....15.61 BasophilsObservation
....15.62 CMVDNAViralLoadCopiesmL
....15.63 CMVDNAViralLoadIUmL
....15.64 CMVIgAbPresenceSNOMED
....15.65 CMVIgGAbPresenceLOINC
....15.66 CMVIgMAbPresenceLOINC
....15.67 CMVIgMAbPresenceSNOMED
....15.68 Cytogenetics-Example-1
....15.69 EosinophilsObservation
....15.70 HemoglobinObservation
....15.71 LeukocytesObservation
....15.72 Medication-Cyclophosphamide-Example
....15.73 Medication-Etoposide-Example
....15.74 Medication-GVHD-Prophylaxis-Example
....15.75 Medication-Mobilizing-Agent-Example
....15.76 Medication-Peri-Transplant-Example
....15.77 Medication-Post-HCT-Disease-Therapy-Example
....15.78 Medication-Prep-Regimen-Example
....15.79 Medication-PriorExposure-Example
....15.80 MedicationAdministration-Example1
....15.81 MedicationAdministration-Example2
....15.82 MedicationRequest-Etoposide-Example
....15.83 MetamyelocytesObservation
....15.84 NeutrophilsObservation
....15.85 PatientExample1
....15.86 PatientExample2
....15.87 PatientExample3
....15.88 PatientExample4
....15.89 PatientExample5
....15.90 PatientExample6